Loading
AT101 is an experimental CAR-T cell therapy from AbClon in phase 2 trials for hodgkin lymphoma, aimed at CD19.
AT101 is a CAR-T cell therapy developed by AbClon. Its target is CD19 (the sponsor names CD19). The sponsor states: Autologous chimeric antigen receptor (CAR) T cells engineered to recognise CD19 on B-cell non-Hodgkin lymphoma cells. ClinicalTrials.gov describes the intervention as: Anti-CD19 Chimeric Antigen Receptor T cell. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT05338931, plans to enrol 82 participants with primary completion expected 2030-03-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Autologous chimeric antigen receptor (CAR) T cells engineered to recognise CD19 on B-cell non-Hodgkin lymphoma cells. Connects to CD19.
1.AT101 slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AT101" OR ABSTRACT:"AT101" OR TITLE:"AT101 Anti-CD19 Chimeric Antigen Receptor T cell" OR ABSTRACT:"AT101 Anti-CD19 Chimeric Antigen Receptor T cell") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AT101, not a curated reading list.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares CD19 and the tag pipeline.